A Randomized 26-Week Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD.

Trial Profile

A Randomized 26-Week Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Formoterol; Mometasone; Mometasone/formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2012 Results at 26 weeks presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 27 Oct 2011 HRQOL results for this trial and the identical phase III trial (NCT00383721; clinical trial profile 28826) were presented together at the 77th Annual Meeting of the American College of Chest Physicians: Chest 2011.
    • 24 Oct 2011 Results from this trial have been presented at the 77th Annual Meeting of the American College of Physicians, according to a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top